Yes, Lyrica (pregabalin) is a federally controlled substance. The DEA classifies it as a Schedule V controlled substance, the least restrictive category, placing it in the same regulatory tier as certain cough syrups containing small amounts of codeine. This scheduling means your prescriptions are tracked, refills may be limited depending on your state, and pharmacies handle it differently than non-controlled medications.
Why Lyrica Is Classified as Schedule V
Pregabalin was placed into Schedule V when it first received FDA approval in 2005. The scheduling was based on evidence that the drug carries some potential for misuse, though less than medications in higher schedules like Schedule II (oxycodone) or Schedule IV (benzodiazepines like Xanax).
Pregabalin is a derivative of GABA, a brain chemical that calms nerve activity. It works by blocking certain calcium channels in nerve cells, which reduces the release of signaling chemicals involved in pain and anxiety. At higher doses, this mechanism can produce euphoria, deep relaxation, increased sociability, and sedative or even mild psychedelic-like effects. Those properties are what give it misuse potential, particularly among people who take it in doses well above what’s prescribed.
Who Is Most Likely to Misuse It
For most patients, pregabalin carries a low risk of misuse at prescribed doses. A large German study tracking over 53,000 patients found that about 1.7% were prescribed doses that exceeded the maximum therapeutic ceiling of 600 mg per day, a marker researchers used to flag potential misuse. That’s a small fraction, but the profile of those patients tells a clearer story about who is at higher risk.
Among patients flagged for potential misuse, 42% had a prior history of substance use disorders, compared to 12% in the general pregabalin population. About 34% had previously been prescribed benzodiazepines, and 41% had received opioid prescriptions in the year before starting pregabalin. The gender balance also flipped: while most pregabalin patients overall were female, 61% of those misusing it were male, and most were between 30 and 60 years old.
These patients also showed distinct prescription patterns. They averaged 13 prescriptions per year from three different physicians, compared to six prescriptions from two physicians among typical patients. That pattern of visiting multiple prescribers is a common signal of misuse behavior with controlled substances.
What This Means for Your Prescription
Because Lyrica is a controlled substance, there are practical differences you’ll notice compared to picking up a non-controlled medication. Pharmacies log every fill in a state prescription drug monitoring program (PDMP), which allows doctors and pharmacists to see your fill history across providers. In most states, Schedule V medications can be refilled up to five times within six months of the original prescription date, though some states impose tighter rules.
Your doctor may ask you to come in for regular appointments before writing new prescriptions rather than calling them in indefinitely. Some insurance plans also require prior authorization for Lyrica specifically because both its controlled status and its cost (brand-name Lyrica is significantly more expensive than generic pregabalin) trigger additional review.
A handful of states have reclassified pregabalin more strictly than the federal Schedule V designation, so the exact rules you encounter at the pharmacy can vary depending on where you live. If you’re unsure about your state’s requirements, your pharmacist can tell you exactly what applies.
Dependence and Withdrawal
Controlled substance status and physical dependence are related but separate issues. Even at prescribed doses, your body can become physically dependent on pregabalin over time, meaning you’ll experience withdrawal symptoms if you stop abruptly. This happens with many medications that aren’t controlled at all (certain antidepressants, for example), so dependence alone isn’t a sign of misuse.
Withdrawal symptoms from pregabalin can include insomnia, headache, nausea, anxiety, diarrhea, and in some cases a return of the pain or seizures the drug was managing. The prescribing guidelines recommend tapering rather than stopping cold turkey. A typical taper reduces your daily dose by 50 to 100 mg per week, though your doctor may adjust that pace depending on how long you’ve been taking it and at what dose. The manufacturer’s labeling suggests the drug can be discontinued over the course of one week, but a slower taper allows your doctor to watch for symptoms that resurface along the way.
How It Compares to Similar Medications
Gabapentin (Neurontin), which is structurally similar to pregabalin and treats many of the same conditions, is not a federally controlled substance. This is one of the most common points of confusion for patients, since the two drugs work through nearly identical mechanisms. The difference in scheduling comes down to pregabalin’s faster absorption and more predictable dose response, which give it a somewhat higher potential for producing euphoria at elevated doses.
That said, several states have independently moved to classify gabapentin as a controlled substance at the state level in response to rising misuse reports, so the regulatory gap between the two drugs has been narrowing in practice. If you’re switching between these medications, the controlled substance status of each one in your specific state will affect how your prescriptions are handled.